Northland Biotech's Sedominji Completes First National Shipment – World's First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces
CompanyDrug

Northland Biotech’s Sedominji Completes First National Shipment – World’s First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

Beijing Northland Biotechnology Co., Ltd. announced that its independently developed Class 1 innovative gene therapy, Sedominji Injection (brand name: Huasuoling®), completed its first nationwide shipment at the production base of…

GeneScience's GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody
CompanyDrug

GeneScience’s GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody

Youcare Pharmaceutical's YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program
CompanyDrug

Youcare Pharmaceutical’s YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties
CompanyDeals

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo
CompanyDrug

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo

- Advertisement -
Ad image
BeOne Medicines Announces Imdelltra (Tarlatamab), First‑in‑Class DLL3/CD3 T‑Cell Engager Co‑Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities
CompanyDrug

BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities

CompanyDeals

Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL

CompanyDrug

Astellas Submits NDA in Japan for Fezolinetant, a First-in-Class Nonhormonal NK3 Receptor Antagonist for Menopausal Vasomotor Symptoms

Xtalpi and Gan & Lee Pharmaceuticals' AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration
CompanyDeals

Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration

Others

CrystalO Biopharma Signs Collaboration and Licensing Deal With Almirall for AI‑Driven Skin Disease Drug Discovery, Worth Up to €254.5 Million

CompanyDeals

Tonghua Golden‑Horse Unit Signs M&A Intent Agreement to Acquire Controlling Stake in 8PLUS1 Pharma

CompanyDeals

Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

CompanyMedical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
CompanyDeals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

CompanyDrug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

CompanyDeals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Show More